United States API Contract Manufacturing Market Insight
Published: 28 May 2026 | Report Format: Electronic (PDF)
US is witnessing substantial expansion, with an estimated CAGR of around 8.59%, driven primarily by rising pharmaceutical outsourcing activities, increasing demand for complex active pharmaceutical ingredients (APIs)
U.S. API Contract Manufacturing Market Insights Forecasts to 2035
- The US API Contract Manufacturing Market Size Was Estimated at USD 39.81 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 8.59% from 2025 to 2035
- The US API Contract Manufacturing Market Size is Expected to Reach USD 90.75 Billion by 2035
Notable Insights for U.S. API Contract Manufacturing Market
- Small molecule APIs accounted for nearly 64% of the United States API contract manufacturing market in 2025, owing to strong commercial demand for generic pharmaceuticals, cardiovascular drugs, oncology therapies, and high-volume prescription medications.
- According to the synthesis segment of the market, synthetic API manufacturing represented approximately 58% of total market share due to large-scale pharmaceutical production capabilities, cost-efficient processing technologies, and strong domestic demand for chemically synthesized drug compounds.
- The United States pharmaceutical industry generated over USD 630 Billion in annual economic output in 2025, reinforcing strong long-term demand for contract API production, biologics manufacturing, and specialty pharmaceutical outsourcing services.
- Biopharmaceutical outsourcing activity increased by approximately 14% in 2025 due to the growing development of personalized medicine, cell and gene therapies, and high-potency APIs requiring specialized manufacturing capabilities.
Download the eBook (ToC)
Why Buy This Report
- Gather highly specific and strategic information about the API contract manufacturing market in the United States, including developments in biologics production, high-potency API manufacturing, continuous pharmaceutical processing, advanced CDMO services, and regulatory-compliant drug manufacturing technologies transforming the pharmaceutical industry nationwide.
- Learn about changes taking place within the U.S. pharmaceutical manufacturing ecosystem due to supply chain localization, AI-driven pharmaceutical production optimization, advanced biologics manufacturing, personalized medicine expansion, and next-generation drug development technologies.
- Discover emerging opportunities for investment arising from developments in oncology APIs, peptide manufacturing, biologics outsourcing, sterile pharmaceutical production, advanced pharmaceutical automation systems, and high-value specialty drug manufacturing infrastructure.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US API Contract Manufacturing market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States API Contract Manufacturing Market
- Lonza Group AG
- Catalent, Inc.
- Thermo Fisher Scientific Inc.
- Cambrex Corporation
- Pfizer CentreOne
- Boehringer Ingelheim BioXcellence
- Curia Global, Inc.
- Recipharm AB
- Others
Recent Developments:
- In February 2026, Thermo Fisher Scientific Inc. expanded its U.S. pharmaceutical manufacturing network through investments exceeding USD 650 Million focused on biologics production, sterile API manufacturing, and advanced pharmaceutical processing technologies supporting domestic drug supply chain resilience.
- In October 2025, Catalent, Inc. introduced advanced high-potency API manufacturing capabilities across its North American CDMO facilities while investing approximately USD 420 Million toward continuous manufacturing systems and next-generation pharmaceutical automation technologies.
Market Segmentation:
United States API Contract Manufacturing Market, By API Type
- Small Molecule APIs
- Biologic APIs
- Highly Potent APIs (HPAPIs)
- Others
United States API Contract Manufacturing Market, By Synthesis Type
- Synthetic APIs
- Biotech APIs
United States API Contract Manufacturing Market, By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Research Organizations
- Others
Expert Views:
According to market projections, the United States API contract manufacturing market is expected to witness strong long-term growth, driven by increasing pharmaceutical outsourcing, rising biologics production demand, and growing investments in domestic drug manufacturing infrastructure. The rapid expansion of personalized medicine, high-potency pharmaceutical compounds, and advanced biologics development is anticipated to strengthen demand for specialized API contract manufacturing services across the country.
Author: Komal and Radhika By Spherical Insights and Consulting